Literature DB >> 33766120

Bilateral facial nerve palsy associated with amphiphysin antibody in metastatic breast cancer: a case report.

Vineet Kwatra1, Michail Charakidis2, Narayan V Karanth2.   

Abstract

BACKGROUND: Paraneoplastic neurological syndrome is an immune-mediated phenomenon where antibodies from tumor cells are produced against neuronal proteins. Amphiphysin antibody is an onconeural antibody linked to the diagnosis of breast cancer and small-cell lung cancer. It is uncommon and typically associated with stiff-person syndrome, of which 90% of patients are eventually diagnosed with breast cancer. CASE
PRESENTATION: We present a case of a 47-year-old Caucasian woman with metastatic hormone receptor-positive breast cancer who developed bilateral facial nerve palsy while on treatment with nab-paclitaxel. The patient was found to have anti-amphiphysin antibody in the serum and cerebrospinal fluid. She was treated with methylprednisolone and intravenous immunoglobulin, which resulted in partial improvement in her facial nerve palsy.
CONCLUSIONS: This case highlights a rare presentation of bilateral facial nerve palsy that likely related to paraneoplastic syndrome associated with the presence of anti-amphiphysin antibody.

Entities:  

Keywords:  Amphiphysin antibody; Bell’s palsy; Breast cancer; Facial nerve palsy; Nab-paclitaxel; Paraneoplastic syndrome

Mesh:

Substances:

Year:  2021        PMID: 33766120      PMCID: PMC7995578          DOI: 10.1186/s13256-021-02727-3

Source DB:  PubMed          Journal:  J Med Case Rep        ISSN: 1752-1947


  16 in total

1.  [A case of facial nerve palsy induced by nab-paclitaxel].

Authors:  Naoko Minatani; Yoshimasa Kosaka; Norihiko Sengoku; Mariko Kikuchi; Hiroshi Nishimiya; Mina Waraya; Takumo Enomoto; Hirokazu Tanino; Masahiko Watanabe
Journal:  Gan To Kagaku Ryoho       Date:  2013-11

2.  Motor neuropathy due to docetaxel and paclitaxel.

Authors:  R J Freilich; C Balmaceda; A D Seidman; M Rubin; L M DeAngelis
Journal:  Neurology       Date:  1996-07       Impact factor: 9.910

3.  Anti-amphiphysin I antibodies in patients with paraneoplastic neurological disorders associated with small cell lung carcinoma.

Authors:  A Saiz; J Dalmau; M H Butler; Q Chen; J Y Delattre; P De Camilli; F Graus
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-02       Impact factor: 10.154

4.  Antiamphiphysin antibodies are associated with various paraneoplastic neurological syndromes and tumors.

Authors:  J C Antoine; L Absi; J Honnorat; J M Boulesteix; T de Brouker; C Vial; M Butler; P De Camilli; D Michel
Journal:  Arch Neurol       Date:  1999-02

Review 5.  Bilateral simultaneous facial paralysis--differential diagnosis and treatment options. A case report and review of literature.

Authors:  G Gevers; P Lemkens
Journal:  Acta Otorhinolaryngol Belg       Date:  2003

6.  Recommended diagnostic criteria for paraneoplastic neurological syndromes.

Authors:  F Graus; J Y Delattre; J C Antoine; J Dalmau; B Giometto; W Grisold; J Honnorat; P Sillevis Smitt; Ch Vedeler; J J G M Verschuuren; A Vincent; R Voltz
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-08       Impact factor: 10.154

7.  Autoantibodies to a 128-kd synaptic protein in three women with the stiff-man syndrome and breast cancer.

Authors:  F Folli; M Solimena; R Cofiell; M Austoni; G Tallini; G Fassetta; D Bates; N Cartlidge; G F Bottazzo; G Piccolo; P De Camilli
Journal:  N Engl J Med       Date:  1993-02-25       Impact factor: 91.245

8.  A role of amphiphysin in synaptic vesicle endocytosis suggested by its binding to dynamin in nerve terminals.

Authors:  C David; P S McPherson; O Mundigl; P de Camilli
Journal:  Proc Natl Acad Sci U S A       Date:  1996-01-09       Impact factor: 11.205

9.  Antiamphiphysin antibodies with small-cell lung carcinoma and paraneoplastic encephalomyelitis.

Authors:  E J Dropcho
Journal:  Ann Neurol       Date:  1996-05       Impact factor: 10.422

10.  Amphiphysin, a novel protein associated with synaptic vesicles.

Authors:  B Lichte; R W Veh; H E Meyer; M W Kilimann
Journal:  EMBO J       Date:  1992-07       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.